Molecular heterogeneity of hepatocellular carcinoma and its precise treatment in clinical practice

Qiang ZOU; Jun WANG; Liangzhi WEN; Bin WANG; Yi ZHANG

doi:10.3969/j.issn.1001-5256.2021.08.006

Volume 37 Issue 8

Aug. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(8): 1765-1769

PDF( 2840 KB)

Molecular heterogeneity of hepatocellular carcinoma and its precise treatment in clinical practice

DOI: 10.3969/j.issn.1001-5256.2021.08.006

Qiang ZOU^{1, 2},
Jun WANG¹,
Liangzhi WEN¹,
Bin WANG^{1
,
,},
Yi ZHANG^{2
,
,}

1.
Department of Gastroenterology, Daping Hospital, Army Medical University, Chongqing 400042, China
2.
Department of Hepatobiliary Surgery, Chongqing University Cancer Hospital, Chongqing 400042, China

Research funding:

National Natural Science Foundation of China (81872027);

National Natural Science Foundation of China (82002585);

Scientific Research Project of Army Medical University (2019XQY19)

Received Date: 2021-05-28
Accepted Date: 2021-05-28
Published Date: 2021-08-20

Abstract

Abstract

Hepatocellular carcinoma (HCC) is the most common type of liver cancer in China, and high molecular heterogeneity of HCC has caused the limitations in clinical efficacy; therefore, it is of great importance to explore its heterogeneity based on molecular classification and develop individualized diagnosis and treatment strategies. Various high-throughput sequencing techniques and multi-omics techniques in recent years have helped to establish multiple molecular classification systems, which gives us a deeper understanding of the molecular heterogeneity of HCC. This article summarizes the molecular classifications of HCC and discusses their association with clinicopathological features. This article also analyzes the new targets for molecular targeted therapy and immunotherapy and proposes new ideas for precise diagnosis and individualized treatment of HCC.
- Carcinoma, Hepatocellular,
- Genetic Heterogeneity,
- Therapeutics

FullText(HTML)

References(40)

References

[1]	CRAIG AJ, VON FELDEN J, GARCIA-LEZANA T, et al. Tumour evolution in hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(3): 139-152. DOI: 10.1038/s41575-019-0229-4.
[2]	BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
[3]	BRUIX J, REIG M, SHERMAN M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma[J]. Gastroenterology, 2016, 150(4): 835-853. DOI: 10.1053/j.gastro.2015.12.041.
[4]	WU Y, LIU Z, XU X. Molecular subtyping of hepatocellular carcinoma: A step toward precision medicine[J]. Cancer Commun (Lond), 2020, 40(12): 681-693. DOI: 10.1002/cac2.12115.
[5]	GONG J, CHEHRAZI-RAFFLE A, REDDI S, et al. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: A comprehensive review of registration trials and future considerations[J]. J Immunother Cancer, 2018, 6(1): 8. DOI: 10.1186/s40425-018-0316-z.
[6]	LLOVET JM, ZUCMAN-ROSSI J, PIKARSKY E, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2016, 2: 16018. DOI: 10.1038/nrdp.2016.18.
[7]	LLOVET JM, BRU' C, BRUIX J. Prognosis of hepatocellular carcinoma: The BCLC staging classification[J]. Semin Liver Dis, 1999, 19(3): 329-338. DOI: 10.1055/s-2007-1007122.
[8]	BANNASCH P, RIBBACK S, SU Q, et al. Clear cell hepatocellular carcinoma: Origin, metabolic traits and fate of glycogenotic clear and ground glass cells[J]. Hepatobiliary Pancreat Dis Int, 2017, 16(6): 570-594. DOI: 10.1016/S1499-3872(17)60071-7.
[9]	FAIVRE S, RIMASSA L, FINN RS. Molecular therapies for HCC: Looking outside the box[J]. J Hepatol, 2020, 72(2): 342-352. DOI: 10.1016/j.jhep.2019.09.010.
[10]	ERSTAD DJ, FUCHS BC, TANABE KK. Molecular signatures in hepatocellular carcinoma: A step toward rationally designed cancer therapy[J]. Cancer, 2018, 124(15): 3084-3104. DOI: 10.1002/cncr.31257.
[11]	CHIANG DY, VILLANUEVA A, HOSHIDA Y, et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma[J]. Cancer Res, 2008, 68(16): 6779-6788. DOI: 10.1158/0008-5472.CAN-08-0742.
[12]	SCHULZE K, IMBEAUD S, LETOUZÉ E, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets[J]. Nat Genet, 2015, 47(5): 505-511. DOI: 10.1038/ng.3252.
[13]	FUJIMOTO A, FURUTA M, TOTOKI Y, et al. Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer[J]. Nat Genet, 2016, 48(5): 500-509. DOI: 10.1038/ng.3547.
[14]	LEE JS, CHU JS, CHU IS, HEO J, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling[J]. Hepatology, 2004, 40(3): 667-676. DOI: 10.1002/hep.20375.
[15]	JIANG X, KIM HE, SHU H, et al. Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway[J]. Science, 2003, 299(5604): 223-226. DOI: 10.1126/science.1076807.
[16]	SEMENZA GL. Targeting HIF-1 for cancer therapy[J]. Nat Rev Cancer, 2003, 3(10): 721-732. DOI: 10.1038/nrc1187.
[17]	LEE JS, HEO J, LIBBRECHT L, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells[J]. Nat Med, 2006, 12(4): 410-416. DOI: 10.1038/nm1377.
[18]	BOYAULT S, RICKMAN DS, de REYNIÈS A, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets[J]. Hepatology, 2007, 45(1): 42-52. DOI: 10.1002/hep.21467.
[19]	HOSHIDA Y, NIJMAN SM, KOBAYASHI M, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma[J]. Cancer Res, 2009, 69(18): 7385-7392. DOI: 10.1158/0008-5472.CAN-09-1089.
[20]	ZAVADIL J, BÖTTINGER EP. TGF-beta and epithelial-to-mesenchymal transitions[J]. Oncogene, 2005, 24(37): 5764-5774. DOI: 10.1038/sj.onc.1208927.
[21]	GIANNELLI G, BERGAMINI C, FRANSVEA E, et al. Laminin-5 with transforming growth factor-beta1 induces epithelial to mesenchymal transition in hepatocellular carcinoma[J]. Gastroenterology, 2005, 129(5): 1375-1383. DOI: 10.1053/j.gastro.2005.09.055.
[22]	HOPPLER S, KAVANAGH CL. Wnt signalling: Variety at the core[J]. J Cell Sci, 2007, 120(Pt 3): 385-393. DOI: 10.1242/jcs.03363.
[23]	MUTO Y, MORIWAKI H, SHIRATORI Y. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma[J]. Digestion, 1998, 59(Suppl 2): 89-91. DOI: 10.1159/000051435.
[24]	ZHANG Y, WANG G, MA W, et al. CdS p-n heterojunction co-boosting with Co(3)O(4) and Ni-MOF-74 for photocatalytic hydrogen evolution[J]. Dalton Trans, 2018, 47(32): 11176-11189. DOI: 10.1039/c8dt02294a.
[25]	HANAHAN D, WEINBERG RA. Hallmarks of cancer: The next generation[J]. Cell, 2011, 144(5): 646-674. DOI: 10.1016/j.cell.2011.02.013.
[26]	DÉSERT R, ROHART F, CANAL F, et al. Human hepatocellular carcinomas with a periportal phenotype have the lowest potential for early recurrence after curative resection[J]. Hepatology, 2017, 66(5): 1502-1518. DOI: 10.1002/hep.29254.
[27]	YANG C, HUANG X, LIU Z, et al. Metabolism-associated molecular classification of hepatocellular carcinoma[J]. Mol Oncol, 2020, 14(4): 896-913. DOI: 10.1002/1878-0261.12639.
[28]	SHANKARAIAH RC, CALLEGARI E, GUERRIERO P, et al. Metformin prevents liver tumourigenesis by attenuating fibrosis in a transgenic mouse model of hepatocellular carcinoma[J]. Oncogene, 2019, 38(45): 7035-7045. DOI: 10.1038/s41388-019-0942-z.
[29]	DUFFY AG, ULAHANNAN SV, MAKOROVA-RUSHER O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma[J]. J Hepatol, 2017, 66(3): 545-551. DOI: 10.1016/j.jhep.2016.10.029.
[30]	EL-KHOUEIRY AB, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502. DOI: 10.1016/S0140-6736(17)31046-2.
[31]	KILLOCK D. Immunotherapy: Nivolumab keeps HCC in check and opens avenues for checkmate[J]. Nat Rev Clin Oncol, 2017, 14(7): 392. DOI: 10.1038/nrclinonc.2017.70.
[32]	JIANG Y, SUN A, ZHAO Y, et al. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma[J]. Nature, 2019, 567(7747): 257-261. DOI: 10.1038/s41586-019-0987-8.
[33]	GAO Q, ZHU H, DONG L, et al. Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma[J]. Cell, 2019, 179(2): 561-577. e22. DOI: 10.1016/j.cell.2019.08.052.
[34]	SIA D, JIAO Y, MARTINEZ-QUETGLAS I, et al. Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features[J]. Gastroenterology, 2017, 153(3): 812-826. DOI: 10.1053/j.gastro.2017.06.007.
[35]	KUREBAYASHI Y, OJIMA H, TSUJIKAWA H, et al. Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification[J]. Hepatology, 2018, 68(3): 1025-1041. DOI: 10.1002/hep.29904.
[36]	KIM HD, SONG GW, PARK S, et al. Association between expression level of PD1 by tumor-infiltrating CD8⁺T cells and features of hepatocellular carcinoma[J]. Gastroenterology, 2018, 155(6): 1936-1950. e17. DOI: 10.1053/j.gastro.2018.08.030.
[37]	ZHANG Q, LOU Y, YANG J, et al. Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas[J]. Gut, 2019, 68(11): 2019-2031. DOI: 10.1136/gutjnl-2019-318912.
[38]	LIM HY, HEO J, CHOI HJ, et al. A phase Ⅱ study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma[J]. Clin Cancer Res, 2014, 20(23): 5976-5985. DOI: 10.1158/1078-0432.CCR-13-3445.
[39]	HO DWH, CHAN LK, CHIU YT, et al. TSC1/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication[J]. Gut, 2017, 66(8): 1496-1506. DOI: 10.1136/gutjnl-2016-312734.
[40]	SUN W, LI SC, XU L, et al. High FLT3 levels may predict sorafenib benefit in hepatocellular carcinoma[J]. Clin Cancer Res, 2020, 26(16): 4302-4312. DOI: 10.1158/1078-0432.CCR-19-1858.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1)

Get Citation

PDF

XML

Article Metrics

Article views (863) PDF downloads(177)

Molecular heterogeneity of hepatocellular carcinoma and its precise treatment in clinical practice

DOI: 10.3969/j.issn.1001-5256.2021.08.006

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Molecular heterogeneity of hepatocellular carcinoma and its precise treatment in clinical practice

DOI: 10.3969/j.issn.1001-5256.2021.08.006

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content